CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.37), $0.20 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $5.66 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.